These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 27258610)

  • 21. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.
    Palma M; Gentilcore G; Heimersson K; Mozaffari F; Näsman-Glaser B; Young E; Rosenquist R; Hansson L; Österborg A; Mellstedt H
    Haematologica; 2017 Mar; 102(3):562-572. PubMed ID: 27927767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SLP76 integrates into the B-cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with an aggressive disease course.
    Dezorella N; Katz BZ; Shapiro M; Polliack A; Perry C; Herishanu Y
    Haematologica; 2016 Dec; 101(12):1553-1562. PubMed ID: 27443285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clonal evolution in chronic lymphocytic leukemia: impact of subclonality on disease progression.
    Sutton LA; Rosenquist R
    Expert Rev Hematol; 2015 Feb; 8(1):71-8. PubMed ID: 25345442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression profiling of B cell chronic lymphocytic leukemia suggests deficient CD1-mediated immunity, polarized cytokine response, altered adhesion and increased intracellular protein transport and processing of leukemic cells.
    Zheng Z; Venkatapathy S; Rao G; Harrington CA
    Leukemia; 2002 Dec; 16(12):2429-37. PubMed ID: 12454749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proliferation centres of chronic lymphocytic leukaemia/small lymphocytic lymphoma have enhanced expression of MYC protein, which does not result from rearrangement or gain of the MYC gene.
    Gibson SE; Leeman-Neill RJ; Jain S; Piao W; Cieply KM; Swerdlow SH
    Br J Haematol; 2016 Oct; 175(1):173-5. PubMed ID: 26568397
    [No Abstract]   [Full Text] [Related]  

  • 26. Characterization of immunoglobulin heavy and light chain gene expression in chronic lymphocytic leukemia and related disorders.
    Nakahashi H; Tsukamoto N; Hashimoto Y; Koiso H; Yokohama A; Saitoh T; Uchiumi H; Handa H; Murakami H; Nojima Y; Karasawa M
    Cancer Sci; 2009 Apr; 100(4):671-7. PubMed ID: 19220298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer: When catastrophe strikes a cell.
    Tubio JM; Estivill X
    Nature; 2011 Feb; 470(7335):476-7. PubMed ID: 21350479
    [No Abstract]   [Full Text] [Related]  

  • 28. Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features.
    Bomben R; Dal-Bo M; Benedetti D; Capello D; Forconi F; Marconi D; Bertoni F; Maffei R; Laurenti L; Rossi D; Del Principe MI; Luciano F; Sozzi E; Cattarossi I; Zucchetto A; Rossi FM; Bulian P; Zucca E; Nicoloso MS; Degan M; Marasca R; Efremov DG; Del Poeta G; Gaidano G; Gattei V
    Clin Cancer Res; 2010 Jan; 16(2):620-8. PubMed ID: 20068100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia.
    Nakagawa Y; Yamaguchi S; Hasegawa M; Nemoto T; Inoue M; Suzuki K; Hirokawa K; Kitagawa M
    Leuk Res; 2004 May; 28(5):487-94. PubMed ID: 15068902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined PER2 and CRY1 expression predicts outcome in chronic lymphocytic leukemia.
    Eisele L; Prinz R; Klein-Hitpass L; Nückel H; Lowinski K; Thomale J; Moeller LC; Dührsen U; Dürig J
    Eur J Haematol; 2009 Oct; 83(4):320-7. PubMed ID: 19500131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Up-regulation of CXCL8/interleukin-8 production in response to CXCL12 in chronic lymphocytic leukemia.
    Perbellini O; Cioffi F; Malpeli G; Zanolin E; Lovato O; Scarpa A; Pizzolo G; Scupoli MT
    Leuk Lymphoma; 2015 Jun; 56(6):1897-900. PubMed ID: 25347424
    [No Abstract]   [Full Text] [Related]  

  • 32. Constitutive activation of NF-κB signaling by NOTCH1 mutations in chronic lymphocytic leukemia.
    Xu ZS; Zhang JS; Zhang JY; Wu SQ; Xiong DL; Chen HJ; Chen ZZ; Zhan R
    Oncol Rep; 2015 Apr; 33(4):1609-14. PubMed ID: 25633905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic recombination.
    Nat New Biol; 1973 May; 243(122):1. PubMed ID: 17319067
    [No Abstract]   [Full Text] [Related]  

  • 34. Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia.
    Enjuanes A; Benavente Y; Bosch F; Martín-Guerrero I; Colomer D; Pérez-Alvarez S; Reina O; Ardanaz MT; Jares P; García-Orad A; Pujana MA; Montserrat E; de Sanjosé S; Campo E
    Cancer Res; 2008 Dec; 68(24):10178-86. PubMed ID: 19074885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma.
    Ghobrial IM; Bone ND; Stenson MJ; Novak A; Hedin KE; Kay NE; Ansell SM
    Mayo Clin Proc; 2004 Mar; 79(3):318-25. PubMed ID: 15008605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aberrant levels of SUV39H1 and SUV39H2 methyltransferase are associated with genomic instability in chronic lymphocytic leukemia.
    Carvalho Alves-Silva J; do Amaral Rabello D; Oliveira Bravo M; Lucena-Araujo A; Madureira de Oliveira D; Morato de Oliveira F; Magalhaes Rego E; Pittella-Silva F; Saldanha-Araujo F
    Environ Mol Mutagen; 2017 Dec; 58(9):654-661. PubMed ID: 28833505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities.
    Mittal AK; Hegde GV; Aoun P; Bociek RG; Dave BJ; Joshi AD; Sanger WG; Weisenburger DD; Joshi SS
    Int J Mol Med; 2007 Oct; 20(4):461-9. PubMed ID: 17786276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.
    Schroers R; Griesinger F; Trümper L; Haase D; Kulle B; Klein-Hitpass L; Sellmann L; Dührsen U; Dürig J
    Leukemia; 2005 May; 19(5):750-8. PubMed ID: 15759031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High expression of hematopoietic cell specific Lyn substrate-1 (HS1) predicts poor survival of B-cell chronic lymphocytic leukemia patients.
    Butrym A; Majewski M; Dzietczenia J; Kuliczkowski K; Mazur G
    Leuk Res; 2012 Jul; 36(7):876-80. PubMed ID: 22333038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The double life of Holliday junctions.
    Liberi G; Foiani M
    Cell Res; 2010 Jun; 20(6):611-3. PubMed ID: 20502439
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.